Labcorp Holdings Inc. (LH) · Oct 28, 2026 · Earnings

Labcorp earnings beat as 2026 guidance rises on broad growth

Beat — Adjusted EPS $4.78 vs ~$4.64 consensus; revenue $3.81B vs ~$3.76B

Labcorp’s Q3 earnings beat expectations, with stronger margins and a raised 2026 revenue and adjusted EPS outlook.

Labcorp is executing a two-part growth strategy: expand higher-value specialty diagnostics while rebuilding momentum in biopharma laboratory services through acquisitions, partnerships and operating efficiencies. Its 2026 Investor Day had already set expectations for above-market growth and long-term expansion in specialty testing, diagnostics and drug-development services.

The quarter cleared both major benchmarks. Adjusted EPS was $4.78 versus published consensus of roughly $4.64, while revenue was $3.81 billion versus approximately $3.76 billion expected. That is a real beat, not merely a margin-driven result: revenue rose 6.9% year over year, with 5.5% organic growth (Revenue Summary), and adjusted operating margin expanded to 15.0% from 14.4% (Earnings Summary). The published consensus figures are third-party estimates; the filing itself provides the year-over-year comparisons.

MetricQ3 2026Q3 2025 / expectationRead
Revenue$3,810.0M$3,563.5M; ~$3,760M consensus6.9% growth; beat
Adjusted EPS$4.78$4.18; ~$4.64 consensus14.5% growth; beat
Adjusted operating margin15.0%14.4%+60 bps
Operating cash flow$563.8M$387.2MHigher year over year
Free cash flow$412.2M$280.5MHigher year over year
2026 adjusted EPS guidance$18.30–$18.70$18.10–$18.55 priorRaised
2026 enterprise revenue guidance$14,779M–$14,887M$14,710M–$14,827M priorRaised

The beat was broad rather than dependent on one segment. Diagnostics revenue grew 6.5% and its adjusted margin widened 40 basis points to 16.7%, while Biopharma Laboratory Services grew 8.5% and expanded margin 180 basis points to 18.3% (Segment Results). Biopharma was the more notable upside contributor, with Central Labs revenue up 11.5%, although Early Development growth was only 0.4% (Biopharma Laboratory Services results). The company’s own summary captures the operating trend: “Labcorp delivered another strong quarter with 7% revenue growth, continued margin expansion and 14.5% adjusted EPS growth, leading to a raise in our full-year guidance.”

The guidance increase strengthens the underlying story, but the magnitude is measured. The enterprise revenue range moved up by roughly $50 million at the low end and $60 million at the high end, while adjusted EPS increased by $0.20 at the low end and $0.15 at the high end (2026 Guidance). Biopharma received the largest proportional revenue upgrade, with its growth outlook lifted to 7.4%–8.4% from 5.5%–6.5%; Diagnostics was raised more modestly to 5.5%–6.2% from 5.3%–6.0% (2026 Guidance). Free-cash-flow guidance was unchanged at $1.24 billion–$1.36 billion, so the update is primarily an earnings and revenue signal rather than a cash-generation surprise.

Cash generation gives the growth investment more support. Nine-month operating cash flow rose to $1.20 billion from $1.03 billion, and free cash flow reached $796.6 million versus $715.7 million a year earlier (Cash Flow Summary). Labcorp spent $683.4 million on acquisitions through nine months, versus $324.0 million in the prior-year period (Cash Flow statement), meaning the company is funding a more active expansion program while still reducing diluted shares year over year to 82.1 million from 84.0 million (Income Statement).

Bottom line: This is a genuine upside quarter: Labcorp beat expectations, expanded margins in both businesses and raised its full-year revenue and adjusted EPS outlook. The surprise is meaningful, though the guidance lift is incremental rather than a wholesale reset of the growth story.

Original filing on SEC EDGAR

More Labcorp Holdings Inc. news

Labcorp earnings beat as 2026 guidance rises on broad growth | LH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.